Skip to main content


Professor Naveena Singh

Professor Naveena Singh (1964-2023) was a renowned gynaecological histopathologist with a special interest in gynaecological cancer. She was a consultant pathologist at Barts Health NHS Trust, becoming an honorary professor at Barts and the London School of Medicine and Dentistry, Queen Mary University of London. Prior to moving to Canada, she served as president of the British Association of Gynecological Pathologists from 2016 to 2019. In 2021, she took up the posts of clinical professor at the University of British Columbia (UBC) and anatomic pathologist at Vancouver General Hospital, Canada. Naveena was a leading member of the Education Committee of the International Society of Gynecological Pathologists. She was also an active member of expert committees, including the European Society of Medical Oncology and the International Collaboration in Cancer Reporting. 

Naveena led national and international collaborative studies and contributed to many research trials and quality improvement projects, focusing on improving accuracy and precision in gynaecological histopathology reporting. Her work helped to refine the reporting of different gynaecological cancers and was incorporated into guidelines, book chapters and scientific articles. She led and co-authored multiple chapters in the World Health Organization Classification of Female Genital Tumours. Amongst her research accomplishments, criteria she developed for the assessment of specific aggressive ovarian cancers were adopted by the International Collaboration on Cancer Reporting, College of American Pathologists, Royal College of Pathologists and were featured by the World Health Organization. In recent years, she devoted her attention to the implementation of molecular classification of endometrial carcinoma into routine diagnostic practice. In 2021–2022, she led a successful application to make POLE testing accessible to all endometrial cancer patients in England, alongside a testing algorithm endorsed by the British Gynaecological Cancer Society. Moving to Canada, she worked on joint projects between UBC and multiple NHS centres in the UK on the impact of tumour genetics in the management of uterine cancers.

Return to top